Biodesix Inc (BDSX) Financial Statements
Industry: Medical Laboratories (Services)
In fiscal 2025, Biodesix reported revenue of $88.5M, up 24.1% from $71.3M the year before. Net income was -$35.3M (a -39.8% net margin), or -$4.67 per diluted share. Operating margin was -31.5%. Operating activities generated -$23.3M of cash, leaving -$23.5M of free cash flow. At fiscal year end, Biodesix held $87.5M in total assets against $89.9M in total liabilities, including $19.0M of cash and equivalents.
Open the full interactive Biodesix financials → Quarterly statements, key ratios, valuation history and price charts.
Biodesix Key Stats
| Share Price | $25.00 |
|---|---|
| Market Cap | $257.4M |
| Revenue YoY Growth | +24.1% |
| 52-Week Range | $5.46 – $30.60 |
| Shares Outstanding | 10.3 million (basic, 2026 Q2) |
Biodesix Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $45.6M | $54.5M | $38.2M | $49.1M | $71.3M | $88.5M |
| Operating Income | -$22.9M | -$40.9M | -$50.6M | -$41.3M | -$34.5M | -$27.9M |
| Pre-Tax Income | -$31.4M | -$43.2M | -$65.4M | -$52.1M | -$42.9M | -$35.3M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$31.4M | -$43.2M | -$65.4M | -$52.1M | -$42.9M | -$35.3M |
| Diluted EPS | -$129.60 | -$31.60 | -$31.00 | -$12.80 | -$6.60 | -$4.67 |
Biodesix Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $21.8M | $28.8M | $25.6M | $26.9M |
| Net Income | -$8.7M | -$4.0M | -$7.8M | -$7.3M |
| Diluted EPS | -$1.16 | -$0.53 | -$0.81 | -$0.71 |
Biodesix Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $62.1M | $32.7M | $43.1M | $26.3M | $26.2M | $19.0M |
| Current Assets | $86.1M | $43.6M | $53.3M | $39.7M | $39.5M | $32.5M |
| Total Assets | $121.1M | $76.1M | $92.9M | $99.1M | $97.2M | $87.5M |
| Current Liabilities | $32.1M | $29.0M | $22.8M | $33.4M | $14.3M | $17.4M |
| Total Long-Term Debt | $28.1M | $10.1M | $30.1M | $40.1M | $40.0M | $50.0M |
| Total Liabilities | $79.9M | $56.4M | $72.3M | $94.5M | $76.4M | $89.9M |
| Shareholders' Equity | $41.2M | $19.7M | $20.6M | $4.6M | $20.9M | -$2.5M |
Biodesix Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$21.4M | -$28.2M | -$45.0M | -$22.9M | -$48.6M | -$23.3M |
| Cash From Investing | -$2.9M | -$2.5M | -$3.5M | -$23.1M | -$3.4M | -$403,000 |
| Cash From Financing | $81.1M | $1.3M | $58.9M | $29.1M | $52.0M | $16.4M |
| Free Cash Flow | -$23.3M | -$30.5M | -$48.3M | -$45.8M | -$51.9M | -$23.5M |
Figures from Biodesix's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Biodesix financials page for every line item.
Biodesix Company Profile
| Ticker | BDSX |
|---|---|
| Exchange | Nasdaq |
| Industry | Medical Laboratories (Services) |
| Headquarters | Louisville, Colorado |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001439725 |
Frequently Asked Questions
What was Biodesix's revenue in fiscal 2025?
Biodesix (BDSX) reported revenue of $88.5M for fiscal 2025.
What is Biodesix's annual revenue history?
Biodesix's annual revenue by fiscal year: 2020: $45.6M; 2021: $54.5M; 2022: $38.2M; 2023: $49.1M; 2024: $71.3M; 2025: $88.5M.
What was Biodesix's net income in fiscal 2025?
Biodesix reported net income of -$35.3M for fiscal 2025.
What was Biodesix's earnings per share (EPS) in fiscal 2025?
Biodesix's diluted EPS was -$4.67 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Biodesix generate in fiscal 2025?
Biodesix generated -$23.5M of free cash flow in fiscal 2025.
What was Biodesix's revenue last quarter?
In its most recent reported quarter (2026 Q2), Biodesix reported revenue of $26.9M.
How much debt does Biodesix have?
Biodesix reported $50.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Biodesix are outstanding?
Biodesix reported a weighted average of 10.3 million basic shares outstanding in 2026 Q2.
What is Biodesix's market cap?
Based on its latest closing price, Biodesix (BDSX) has a market capitalization of about $257.4M.
When does Biodesix's fiscal year end?
Biodesix's fiscal year end, as registered with the SEC, is December 31.
Where is Biodesix headquartered?
Biodesix lists its business address in Louisville, Colorado in its SEC filings.